Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

Core Insights - Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases affecting bone health and blood vessel function [3][4] - The company will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, from 1:10-1:40pm ET [1] - The lead candidate, INZ-701, is an enzyme replacement therapy targeting the PPi-Adenosine Pathway, currently in clinical development for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis [4] Company Overview - Inozyme Pharma specializes in the PPi-Adenosine Pathway, where the ENPP1 enzyme plays a crucial role in generating inorganic pyrophosphate (PPi) and adenosine, which are vital for regulating mineralization and controlling smooth muscle cell proliferation in blood vessels [3] - Disruptions in this pathway can lead to severe conditions such as ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL) [3] Product Development - INZ-701 is designed to increase levels of PPi and adenosine, potentially treating multiple diseases caused by deficiencies in these molecules [4] - The therapy aims to correct pathological mineralization and intimal proliferation, addressing significant morbidity and mortality associated with these diseases [4]